4
NEWS
Age affects drugs efficacy
Recent research has found that in olader patients with Type 2
diabetes, the use of sodium-glucose cotransporter 2 (SGLT2)
inhibitors is associated with increased cardiovascular benefits
but also reduced glycaemic control, whereas glucagonlike
peptide 1 (GLP-1) receptor agonists show the opposite
effect, with better glycaemic control but less cardiovascular
protection.
Current clinical guidelines do not recommend different
diabetes treatment approaches on the basis of sex or
age groups, highlighting the uncertainty caused by the
underrepresentation of women and older individuals in
trials. As a result, Researchers conducted a network analysis
to examine whether the efficacy of SGLT2 inhibitors, GLP-1
receptor agonists, and dipeptidyl peptidase 4 (DPP-4) inhibitors
in controlling blood sugar levels or offering cardiovascular
protection varied according to age and sex among adult patients
with T2D.
The analysis included 601 eligible trials, of which 103
provided individual participant data.
In the study, the use of SGLT2 inhibitors was found to
be associated with reduced lowering of HbA1c levels with
increasing age. In contrast, the use of GLP-1 receptor agonists
was linked to greater lowering of A1c levels with increasing age.
The use of DPP-4 inhibitors led to slightly better lowering of
HbA1c levels among older people for dual therapy, but not for
monotherapy or triple therapy.
New CEO for
ViCentra
ViCentra B.V., the company behind
Kaleido, the insulin patch pump and
automated insulin delivery (AID) system,
has announced the appointment
of Tom Arnold as Chief Executive
Officer. Arnold brings almost 25 years
of extensive leadership experience
in diabetes and medical technology
and has a strong track record in
spearheading commercialization
initiatives, business strategy, and
product launches for leading medical
device companies. He has held key
leadership roles at Medtronic, PROCEPT
BioRobotics, Boston Scientific, and Sorin
Group. During his more than seven
years at Medtronic, he played a pivotal
role in launching the world's first hybrid
closed-loop insulin pump system by
driving adoption through innovative
commercialization strategies and
payer access models. He also expanded
patient access to advanced diabetes
management solutions.
UTD launches
Digital Hub
United Through Diabetes (UTD),
the annul in -person event run by
the charity Diabetes Research and
Wellness Foundation (DRWF), has
launched a digital hub, which gives
users the opportunity to recap on
content from the day, plus access
to even more content to help the
management of diabetes.
United Through Diabetes aims
to bring the diabetes community
together with healthcare
professionals, public health officials,
third sector organisations, and
industry partners.
To find out more, CLICK HERE.
HCL roll out continues
The first phase of the roll-out of hybrid closed loop systems to NHS
integrated care systems continues.
Following a successful pilot by NHS England, in December
2023 the National Institute for Health and Care Excellence
recommended that HCL technology should be rolled-out in a phased
implementation, over the next five years, to thousands of Type 1
diabetes patients including:
• Adults who have an HbA1c of 58 mmol/mol (7.5%) or higher, or have
disabling hypoglycaemia, despite best possible management with at
least one of the following:
- continuous subcutaneous insulin infusion
- real-time CGM
- intermittently scanned CGM
• Children and young people (under 18 years old)
• Women, trans men and non-binary people who are pregnant or
planning to become pregnant.
All patients who are eligible are advised to continue to attend
appointments as normal and discuss options with their diabetes team.
To find out more, CLICK HERE.